The high incidence, long treatment duration, and multiple lines of therapy in the treatment of breast cancer represent strong commercial opportunity for drug development. The CDK4\/6 inhibitors (Pfizer\u2019s Ibrance, Novartis\u2019s Kisqali, and Eli Lilly\u2019s Verzenio\/Verzenios) are contributing greatly to treatment options for HR-positive\/HER2-negative disease, a trend that will continue through 2031. The current treatments and clinical pipeline for HER2-positive breast cancer are dynamic as options expand with the launch of novel HER2-targeting agents (Daiichi Sankyo \/ AstraZeneca\u2019s Enhertu, Seagen \/ Pfizer\u2019s Tukysa, and MacroGenics\u2019 Margenza), sales of which will offset the launch of generics and biosimilars. The approval of PARP inhibitors (AstraZeneca \/ Merck & Co.\u2019s Lynparza, Pfizer\u2019s Talzenna), immune checkpoint inhibitors (Roche \/ Genentech \/ Chugai\u2019s Tecentriq, Merck & Co.\u2019s Keytruda), and TROP2-targeted agents (Gilead\u2019s Trodelvy) will further diversify treatment of triple-negative breast cancer.<\/p>\n
QUESTIONS ANSWERED<\/strong><\/p>\n PRODUCT DESCRIPTION<\/strong><\/p>\n Disease Landscape & Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n SOLUTION ENHANCEMENT<\/strong><\/p>\n Disease Landscape & Forecast<\/em> features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n CONTENT HIGHLIGHTS<\/strong><\/p>\n\n
\n